These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9689430)
1. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro. Vogt K; Hahn H Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430 [TBL] [Abstract][Full Text] [Related]
2. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514 [TBL] [Abstract][Full Text] [Related]
3. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Nakao M; Tada M; Tsuchimori K; Uekata M Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):391-9. PubMed ID: 7556227 [TBL] [Abstract][Full Text] [Related]
4. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori. Alarcón T; Domingo D; Sánchez I; Sanz JC; Martínez MJ; López-Brea M Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):275-7. PubMed ID: 9707312 [TBL] [Abstract][Full Text] [Related]
6. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. Malizia T; Tejada M; Marchetti F; Favini P; Pizzarelli G; Campa M; Senesi S J Antimicrob Chemother; 1998 Mar; 41 Suppl B():29-35. PubMed ID: 9579710 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory activities of lansoprazole against respiration in Helicobacter pylori. Nagata K; Sone N; Tamura T Antimicrob Agents Chemother; 2001 May; 45(5):1522-7. PubMed ID: 11302821 [TBL] [Abstract][Full Text] [Related]
8. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori. Nakao M J Clin Gastroenterol; 1995; 20 Suppl 1():S32-7. PubMed ID: 7673612 [TBL] [Abstract][Full Text] [Related]
9. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Iwahi T; Satoh H; Nakao M; Iwasaki T; Yamazaki T; Kubo K; Tamura T; Imada A Antimicrob Agents Chemother; 1991 Mar; 35(3):490-6. PubMed ID: 2039199 [TBL] [Abstract][Full Text] [Related]
10. [Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy]. Tamura K; Murai M; Tanaka M; Kawano S Nihon Rinsho; 1993 Dec; 51(12):3261-6. PubMed ID: 8283644 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Nakao M; Malfertheiner P Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114 [TBL] [Abstract][Full Text] [Related]
12. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Midolo PD; Turnidge JD; Lambert JR; Bell JM Antimicrob Agents Chemother; 1996 Jun; 40(6):1531-3. PubMed ID: 8726032 [TBL] [Abstract][Full Text] [Related]
13. Uptake site of lansoprazole, a proton pump inhibitor, in human fundic mucosa: possible relevance with fibroblast and Helicobacter pylori. Nakamura M; Oda M; Akiba Y; Inoue J; Ito T; Fujiwara T; Tsuchiya M; Ishii H Cell Mol Biol (Noisy-le-grand); 1995 Feb; 41(1):125-30. PubMed ID: 7773126 [TBL] [Abstract][Full Text] [Related]
14. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Pais SA; Nathwani RA; Dhar V; Nowain A; Laine L Aliment Pharmacol Ther; 2006 Jun; 23(11):1607-13. PubMed ID: 16696810 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro. Mégraud F J Clin Gastroenterol; 1995; 20 Suppl 1():S24-7. PubMed ID: 7673610 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. Shimoyama T; Fukuda S; Mikami T; Fukushi M; Munakata A J Gastroenterol; 2004 Oct; 39(10):927-30. PubMed ID: 15549444 [TBL] [Abstract][Full Text] [Related]
17. Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Bamba H; Kondo Y; Wong RM; Sekine S; Matsuzaki F Am J Gastroenterol; 1997 Apr; 92(4):659-62. PubMed ID: 9128318 [TBL] [Abstract][Full Text] [Related]
18. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative]. Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666 [No Abstract] [Full Text] [Related]
19. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. Parente F; Bargiggia S; Bollani S; Colombo E; Bianchi Porro G Hepatogastroenterology; 1998; 45(22):990-3. PubMed ID: 9755995 [TBL] [Abstract][Full Text] [Related]